AlphaMadera's AlphaVal page computes Genpact Limited's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag G as undervalued, fairly valued, or overvalued.

What is Genpact Limited's fair value?

Fair value for G is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value G?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from G's most recent reported fundamentals.

G - Genpact Limited

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $39.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 50% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Strong

Trading 54.0% below fair value

Current Price $30.89

Bear Case $49.80 61.2% upside ($49.80 - $30.89) / $30.89 = 61.2% 6% stage 1 growth, 11% discount

Fair Value $67.15 117.4% upside ($67.15 - $30.89) / $30.89 = 117.4% 10% stage 1 growth, 11% discount

Bull Case $84.02 172.0% upside ($84.02 - $30.89) / $30.89 = 172.0% 13% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

9.6%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (10% base case)

Terminal Value % of EV 39%

Implied Market Multiple 8.7x

Market is pricing in (growth) -2.5% vs our 9.6% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $39.00 from 40 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $67.15 per share.

Warnings

ℹ Wall Street's average price target is $39.00 (from 40 analysts). Our estimate is 103% above the consensus -- consider that gap carefully.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions